Display options
Cite
Schouten PC, Richters L, Vis DJ, et al. Ovarian Cancer-Specific . Clin Cancer Res. 2021;27(23):6559-6569doi: 10.1158/1078-0432.CCR-21-1673.
Schouten, P. C., Richters, L., Vis, D. J., Kommoss, S., van Dijk, E., Ernst, C., Kluin, R. J. C., Marmé, F., Lips, E. H., Schmidt, S., Scheerman, E., Prieske, K., van Deurzen, C. H. M., Burges, A., Ewing-Graham, P. C., Dietrich, D., Jager, A., de Gregorio, N., Hauke, J., du Bois, A., Nederlof, P. M., Wessels, L. F., Hahnen, E., Harter, P., Linn, S. C., & Schmutzler, R. K. (2021). Ovarian Cancer-Specific . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(23), 6559-6569. https://doi.org/10.1158/1078-0432.CCR-21-1673
Schouten, Philip C, et al. "Ovarian Cancer-Specific ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,23 (2021): 6559-6569. doi: https://doi.org/10.1158/1078-0432.CCR-21-1673
Schouten PC, Richters L, Vis DJ, Kommoss S, van Dijk E, Ernst C, Kluin RJC, Marmé F, Lips EH, Schmidt S, Scheerman E, Prieske K, van Deurzen CHM, Burges A, Ewing-Graham PC, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof PM, Wessels LF, Hahnen E, Harter P, Linn SC, Schmutzler RK. Ovarian Cancer-Specific . Clin Cancer Res. 2021 Dec 01;27(23):6559-6569. doi: 10.1158/1078-0432.CCR-21-1673. Epub 2021 Sep 30. PMID: 34593530.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2021 Dec 01;27(23):6559-6569. doi: 10.1158/1078-0432.CCR-21-1673. Epub 2021 Sep 30.

Ovarian Cancer-Specific .

Clinical cancer research : an official journal of the American Association for Cancer Research

Philip C Schouten, Lisa Richters, Daniel J Vis, Stefan Kommoss, Ewald van Dijk, Corinna Ernst, Roelof J C Kluin, Frederik Marmé, Esther H Lips, Sandra Schmidt, Esther Scheerman, Katharina Prieske, Carolien H M van Deurzen, Alexander Burges, Patricia C Ewing-Graham, Dimo Dietrich, Agnes Jager, Nikolaus de Gregorio, Jan Hauke, Andreas du Bois, Petra M Nederlof, Lodewyk F Wessels, Eric Hahnen, Philipp Harter, Sabine C Linn, Rita K Schmutzler

Affiliations

  1. Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands. [email protected].
  2. Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
  3. Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  4. Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  5. Genomics Core Facility, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  6. Department of Gynecologic Oncology, Medical Faculty Mannheim, University of Heidelberg, University Hospital Mannheim, Mannheim, Germany.
  7. Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  8. Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  9. Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  10. Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
  11. Department of Gynecology and Obstetrics, University Hospital Munich-Großhadern, Munich, Germany.
  12. Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany.
  13. Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands.
  14. Department of Gynecology and Obstetrics, University Hospital, University of Ulm, Ulm, Germany.
  15. Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
  16. Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, the Netherlands.
  17. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  18. Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.

PMID: 34593530 DOI: 10.1158/1078-0432.CCR-21-1673

Abstract

PURPOSE: Previously, we developed breast cancer

RESULTS: The detection rate of the

CONCLUSIONS: The newly trained classifiers detected most

©2021 The Authors; Published by the American Association for Cancer Research.

References

  1. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer Groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749–68. - PubMed
  2. Cancer Stat Facts: ovarian cancer. - PubMed
  3. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234–44. - PubMed
  4. Piver MS. Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncology. 2006;20:115658. - PubMed
  5. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24–32. - PubMed
  6. Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49–58. - PubMed
  7. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–8. - PubMed
  8. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7:263–72. - PubMed
  9. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505. - PubMed
  10. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33. - PubMed
  11. Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9. - PubMed
  12. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110–20. - PubMed
  13. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61. - PubMed
  14. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64. - PubMed
  15. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87. - PubMed
  16. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61. - PubMed
  17. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776–82. - PubMed
  18. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517–25. - PubMed
  19. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366–75. - PubMed
  20. Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72:5454–62. - PubMed
  21. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555–61. - PubMed
  22. Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16:475. - PubMed
  23. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636–48. - PubMed
  24. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403–15. - PubMed
  25. Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–402. - PubMed
  26. Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28. - PubMed
  27. Lynparza, Opinion. 2020. - PubMed
  28. Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat. 2009;116:479–89. - PubMed
  29. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002;99:6567–72. - PubMed
  30. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, van Beers EH, et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol. 2011;22:1561–70. - PubMed
  31. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, et al. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014;16:R47. - PubMed
  32. Schouten PC, Marme F, Aulmann S, Sinn HP, van Essen HF, Ylstra B, et al. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. Clin Cancer Res. 2015;21:763–70. - PubMed
  33. Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, et al. BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial. Int J Cancer. 2016;139:882–9. - PubMed
  34. Vliek S, Jager A, Jonge-Lavrencic M, Lotz J-P, Gonçalves A, Graeser M, et al. Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial. Cancer Res. 2018;78:OT2–07–08. - PubMed
  35. Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, et al. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res. 2017;19:99. - PubMed
  36. Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marme F, et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One. 2017;12:e0186043. - PubMed
  37. Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, et al. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). J Med Genet. 2019;56:574–80. - PubMed
  38. Human tissue and medical research: code of conduct for responsible use (2011). 2011. - PubMed
  39. Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, et al. Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Mol Oncol. 2015;9:1274–86. - PubMed
  40. Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, et al. Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. Breast Cancer Res Treat. 2013;139:317–27. - PubMed
  41. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. 2009. - PubMed
  42. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15. - PubMed
  43. Domanska K, Malander S, Staaf J, Karlsson A, Borg A, Jonsson G, et al. Genetic profiles distinguish different types of hereditary ovarian cancer. Oncol Rep. 2010;24:885–95. - PubMed
  44. Kamieniak MM, Munoz-Repeto I, Rico D, Osorio A, Urioste M, Garcia-Donas J, et al. DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas. Br J Cancer. 2013;108:1732–42. - PubMed
  45. Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319. - PubMed
  46. Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet. 2018;50:1262–70. - PubMed
  47. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3. - PubMed
  48. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101. - PubMed
  49. Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16:211. - PubMed
  50. Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018;10:e9172. - PubMed

Publication Types